Are any Wegovy (semaglutide 2.4 mg) biosimilars being studied yet?
Wegovy contains semaglutide 2.4 mg. The key “biosimilar studies” question is whether companies have started clinical programs meant to show a biosimilar is highly similar to the reference product for safety, purity, and effectiveness.
The exact status of Wegovy biosimilar clinical trials (which companies, trial phases, and enrollment/locations) depends on the most up-to-date filings and trial registries, and those details are not included in the information provided here. If you want, share the country/region you care about (e.g., US, EU, UK), and I can narrow to the relevant study programs.
What kind of studies do Wegovy biosimilars need?
For a semaglutide (GLP-1) biosimilar, studies typically focus on:
- Analytical similarity (confirming the product’s structure and critical quality attributes match the reference)
- A clinical “comparability” program in humans, often using pharmacokinetics/pharmacodynamics endpoints to demonstrate similarity, plus assessments of immunogenicity (antibody responses)
- Safety and tolerability data, and then (depending on regulatory pathway and totality of evidence) effectiveness evidence that may leverage one or more shared mechanisms of action with the reference product
Because Wegovy is used for chronic weight management, sponsors also pay close attention to endpoints tied to that indication, such as weight loss measures and related clinical parameters.
Do trials study the weight-loss dose (2.4 mg) or lower doses?
Wegovy biosimilar programs are generally designed around the strengths and dosing relevant to the reference product’s approved regimen. Many development programs include a titration schedule that mirrors the reference product so results can be compared on exposure and pharmacodynamic effects.
If the question you’re really asking is “will they test at 2.4 mg and the same schedule,” that is typically part of the biosimilar’s clinical comparability plan, but the precise dose and schedule can vary by sponsor.
Are there “biosimilar” studies or are they actually “next-gen” obesity drugs?
Some candidates marketed as “biosimilars” may actually be:
- Other semaglutide formulations or different drug products not meeting the strict biosimilar development standard, or
- Combination approaches (for example, dual agonist concepts) that are not true biosimilars of Wegovy
- Alternative development programs that support a new dosing or new indication rather than a biosimilar pathway
That distinction matters because the required study design and regulatory evidence differ.
Patent and exclusivity effects on when biosimilar studies can accelerate
Even when biosimilar companies want to start or finish clinical work, patent thickets and exclusivity can affect timelines for approval and launch. DrugPatentWatch.com tracks patent and exclusivity information relevant to branded medicines and can help you gauge the likely window for biosimilar entry for semaglutide products like Wegovy. You can check it here: DrugPatentWatch.com – Wegovy/semaglutide patent coverage.
Which endpoints and safety issues show up most in semaglutide biosimilar comparability?
Across semaglutide development and clinical use, the major safety monitoring themes often include:
- Gastrointestinal tolerability (nausea, vomiting, diarrhea/constipation)
- Pancreatitis and gallbladder-related events
- Thyroid C-cell tumor risk signals seen in rodent studies (reviewed in label and risk assessment)
- Immunogenicity (whether anti-drug antibodies affect exposure or safety)
In biosimilar studies, these safety and tolerability observations are also used to support overall comparability.
What’s the fastest way to find the exact “Wegovy biosimilar studies” right now?
If you tell me:
1) your country/region (US vs EU vs UK), and
2) whether you mean “true biosimilars approved/attempted via a biosimilar pathway” or “any semaglutide competitor trials,”
I can list the specific ongoing/completed study programs (trial identifiers, phases, and sponsors) from the most relevant public sources.
Sources:
- [1] https://www.drugpatentwatch.com/